Somaxon Slaps Par With 2nd Suit Over Generic Silenor

Law360, New York (May 27, 2011, 9:06 PM EDT) -- Somaxon Pharmaceuticals Inc. hit Par Pharmaceutical Cos. Inc. with a patent infringement suit in Delaware on Thursday, seeking to prevent the release of the generic drug maker's version of Somaxon's prescription insomnia medication Silenor.

Par had informed Somaxon in a letter on May 10 that it was submitting an abbreviated new drug application to the U.S. Food and Drug Administration to get the agency's approval to make and sell 3-milligram and 6-milligram dosages of generic doxepin hydrochloride tablets, which have the same active ingredients and dosage...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.